Shares of Novavax, Inc. (NASDAQ:NVAX - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $7.03, but opened at $6.78. Novavax shares last traded at $6.78, with a volume of 1,072,648 shares trading hands.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on the company. JPMorgan Chase & Co. cut their price objective on Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a research report on Friday, May 9th. B. Riley reissued a "buy" rating on shares of Novavax in a research report on Monday, May 19th. Citigroup began coverage on Novavax in a research report on Tuesday. They set a "sell" rating and a $6.00 price objective for the company. BTIG Research initiated coverage on shares of Novavax in a report on Friday, February 28th. They set a "buy" rating and a $19.00 price target for the company. Finally, TD Cowen upgraded shares of Novavax to a "hold" rating in a report on Thursday, February 27th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $17.00.
View Our Latest Report on Novavax
Novavax Stock Up 1.7%
The company has a 50 day simple moving average of $6.74 and a 200 day simple moving average of $7.64. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of 2.42, a price-to-earnings-growth ratio of 0.07 and a beta of 2.80.
Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 EPS for the quarter, beating the consensus estimate of $0.71 by $2.22. The company had revenue of $666.66 million for the quarter, compared to analyst estimates of $204.08 million. Novavax had a negative return on equity of 115.51% and a net margin of 38.14%. The firm's revenue was up 610.3% compared to the same quarter last year. During the same period last year, the company posted ($1.05) earnings per share. On average, research analysts forecast that Novavax, Inc. will post -1.46 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in shares of Novavax during the 4th quarter valued at approximately $27,000. New Age Alpha Advisors LLC bought a new position in shares of Novavax in the fourth quarter valued at approximately $35,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Novavax during the 1st quarter valued at $71,000. GAMMA Investing LLC lifted its holdings in Novavax by 2,272.5% in the 1st quarter. GAMMA Investing LLC now owns 11,839 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 11,340 shares during the last quarter. Finally, AlphaQuest LLC lifted its stake in Novavax by 290.1% during the fourth quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 7,940 shares during the last quarter. Hedge funds and other institutional investors own 53.04% of the company's stock.
About Novavax
(
Get Free Report)
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Further Reading
Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.